Major adverse cardiac events (death, myocardial infarction, repeat target lesion revascularization) were not different at 30 days (4.3% vs. 4.4%).
Discussion Multistate models have to be used to study this association because the competitive risk between the events "Death" and "Discharge" cannot be handled with the others statistical models.
Results The efficacy evaluation will be based on a composite end point of clinical events (death by any cause, myocardial infarction, stroke, recurrent ischemia requiring hospitalization, or urgent ischemia-driven revascularization).
The primary end point was a composite of evidence-based post-ACS therapies within 24 hours of admission, with the secondary measure of major cardiovascular clinical events (death, nonfatal myocardial infarction, nonfatal cardiac arrest, and nonfatal stroke).
Pluto rules catastrophic events, death, rebuilding, rebirth and transformation.
Four events were considered major adverse events: death, stroke, myocardial infarction, and ESRD.
Specific data forms exist to track samples and to record infectious events, death and drop-out.
Significantly, there were only 20 events (death or progression of disease) during the follow-up period.
Inhospital major adverse events (death, CABG, myocardial infarction) occurred in 62%.
Serious adverse events (death, life-threatening events, or events leading to hospitalization); Other adverse events.
The rates of adverse events (death, falls and readmission to an acute service) did not differ between the groups.
